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Conclusions and recommendations 3Rs impact
Data collection and analysis  Acute inhalation studies are conducted in animals for hazard identifi cation and risk classifi cation. Current accepted methods use death as an endpoint (OECD TG403 and TG436).
 The fi xed concentration procedure (FCP) (draft OECD TG433) uses fewer animals and replaces lethality as an endpoint with 'evident toxicity' -signs that predict exposure to a higher concentration will cause severe toxicity or death in most animals ( Figure 1 ).
 The FCP was dropped from the OECD workplan due to concerns regarding comparable performance with TG403 and TG436, suspected sex diff erences and the subjective nature of evident toxicity. The fi rst two issues have been resolved 1, 2 .
 A global initiative including 19 organisations, led by the NC3Rs, has collected data on the clinical signs observed during inhalation studies in rats. This data has been used to develop a revised TG433 that clearly defi nes evident toxicity clinical signs.
 A clinical signs recording system was developed and used to collect data on over 40 clinical signs observed in individual animals during acute inhalation studies.
 Data for 188 substances, tested in rats at two or more concentrations, were shared by seven laboratories.
 Studies using fi ve rats per group, with no death at the lower dose and at least a two-fold concentration change were selected for analysis. Male and female studies were also analysed separately. 268 pairs of studies were analysed.
 Data were analysed to determine whether clinical signs observed in animals at a lower concentration predict 'toxicity' at a higher concentration. 'Toxicity' was defi ned as death or euthanasia in two or more animals at the higher dose.
 Positive predictive values (PPV), specifi city and sensitivity were determined for clinical signs occuring from day one onwards.
 There was a range of clinical signs recorded, relating to behaviour, posture, appearance, secretions/excretions or respiratory related signs.
 In the absence of death or euthanasia at the same dose, some signs were highly predictive of toxicity at the next highest dose. Table 1 shows the most predictive signs for male and female studies combined. With the exception of ano-genital staining, which was more prevalent in females, there was no signifi cant diff erence between males and females.  Hypoactivity  Irregular respiration  Body weight loss (>10%)  Irregular respiration  Body staining  Ano-genital staining*  Faeces reduced  Naso-ocular discharge  Noisy respiration  Hunched posture  Gasping** *This sign is more prevalent in females than in males. **This sign is more often associated with studies where there is death, once evident toxicity has already been exceeded.
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Increasing predictivity
Toxicity at the next highest dose is highly likely. Substance can be classifi ed according to Outcome B  The data have been used to form a draft recommendation for the recognition of evident toxicity, to provide more guidance on Outcome B in the FCP protocol (Table 2 ).
 These recommendations will be used to propose a revised TG433 that addresses all three areas of concern (i) comparability (ii) potential for sex diff erences and (iii) the recognition of evident toxicity.  Using this guidance, toxicity at the higher dose could have been predicted in 73% of studies. Use of animals at a higher dose would have been avoided.  Adoption of TG433 over currently accepted methods has the potential to reduce animal use and refi ne acute inhalation studies, through the use of evident toxicity rather than death as an endpoint.
